Published in Medical Letter on the CDC and FDA, April 12th, 2006
This announcement is the final approval required by the company to start the third phase of clinical trials with Kamada's flagship alpha 1-proteinase inhibitor drug. The clinical trial will include 50 patients from the U.S. and will follow the protocol submitted to and approved by the FDA.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.